Computer Sciences Corporation (CSC) has announced that DVC, a CSC company, has
successfully vaccinated all volunteers in a Phase I clinical trial for its recombinant
plague vaccine candidate rF1V. The trial is evaluating the safety, tolerability
and immunogenicity of the plague vaccine candidate in 44 healthy volunteers
between the ages of 18 and 40.
The plague vaccine candidate is designed to provide protection against the plague bacterium Yersinia pestis, and was originally identified and developed by scientists working at the U.S. Army Medical Research Institute of Infectious Diseases. Their work involved the identification of suitable protein antigens and the development of the processes used to assess the performance of the vaccine.